![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer Recalls Lot of Xanax Over Out of Specification Result
Pfizer Recalls Lot of Xanax Over Out of Specification Result
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
Pfizer has initiated a voluntary recall of a specific lot of its anxiety drug Xanax after stability testing yielded an out of specification result for an assay at the 46-month stability testing time point.
The affected Xanax (alprazolam) lot was shipped to pharmaceutical distributor Besse Medical between August 2011 and March 2012. The recall was deemed Class 2 by the FDA.
Pfizer has advised Besse to stop distributing the product and quarantine it immediately. It also requested that Besse forward a copy of the request to other wholesalers or retailers to which the drug was distributed.
Pfizer says the affected lot is not likely to cause adverse health consequences.
Upcoming Events
-
21Oct